The Valley Desk

Clinical trial reportThe British journal of dermatologyPublished

SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
The British journal of dermatology
Published
Subject terms
Humans; Psoriasis; Dermatologic Agents; Antibodies, Monoclonal; Body Surface Area; Treatment Outcome; Severity of Illness Index; Double-Blind Method; Adult; Aged; Middle Aged; Female
PubMed ID
40875818
Added to directory
Source checked

Report a correction or request removal